- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
March 1, 2021Amy Churan Named an Insurance Trailblazer by National Law Journal
-
March 1, 2021Firm, Partner Recognized by Managing IP
-
3/1/2021Robins Kaplan Recognized in 2021 World Trademark Review 1000
-
March 6, 2021With Our Voices 2021 Arc Gala
-
March 6, 20211st Annual Tee It Up for the Troops Winter Outing
-
March, 9, 2021The New Frontier of Software License Disputes
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
Winter 2021The Fictional Wealth Disputes That We Took In and Learned From in 2020
-
March 3, 2021Financial Daily Dose 3.3.2021 | Top Story: Rare Merck-J&J Partnership to Boost U.S. Vaccine Production
-
March 2, 2021Financial Daily Dose 3.2.2021 | Top Story: U.S. Markets Bounce Back as Bonds Settle
-
March 1, 2021Financial Daily Dose 3.1.2021 | Top Story: Walmart Poaches Goldman Bankers in Bid to Bolster Fintech Venture
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking Winter 2021
Winter 2021
The Winter 2021 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
A few of the relevant court decisions highlighted in this issue:
- Eli Lilly & Co. v. Apotex, Inc.
Alimta® (pemetrexed disodium)
The Federal Circuit affirmed the district court’s finding that plaintiff’s amendment to replace “ALIMTA” with “pemetrexed disodium” was not a narrowing amendment. - Bracco Diagnostics Inc. v. Maia Pharms., Inc.
Kinevac® (sincalide)
The Federal Circuit affirmed the district court’s judgment based on the parties’ stipulation of infringement that resulted from the the district court’s claim construction. - Par Pharm., Inc. v. Hospira, Inc.
Adrenalin® (epinephrine injection)
The Federal Circuit affirms the trial court’s finding infringement.
Relevant ANDA Updates highlighted in this issue:
Related Professionals
Jeffrey Alan Hovden
Partner
Kelsey J. McElveen
Associate
Haroon N. Mian
Associate
Christopher A. Pinahs
Partner
Reported settlements in federal district court cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Alimta® (pemetrexed disodium)
Kinevac® (sincalide)
Adrenalin® (epinephrine injection)
Jublia® (efinaconazole)
Coreg® (carvedilol)
Impoyz® (clobetasol)
Quillivant XR® (methylphenidate (“MPH”))
Duexis® (ibuprofen / famotidine)
Subscribe to our quarterly GENERICally Speaking Update.
Subscribe Now
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.